Comparing available criteria for measuring brain metastasis response to immunotherapy
Jack M. Qian(South Shore Hospital), Veronica Chiang(Yale University), Harriet M. Kluger(Yale Cancer Center), Apostolos John Tsiouris(Cornell University), James B. Yu(Harvard University), Amit Mahajan(Inova Health System), Sarah B. Goldberg(Yale University)
Cited by 59
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655